Augur Signals
Unlocking Investment Insights with Advanced Financial AI
Find out what Augur Signals does
Find out what Augur Signals does
The Augur Signals is a resourceful hub providing timely insights into investment activity, with a focus on insider transactions across various sectors such as software applications, technology, biotechnology, healthcare, and more. It offers in-depth analyses and reports on significant insider trades that reflect market trends and company strategies, helping investors stay informed about the latest developments.
On May 14, 2024, Rachman Ilya M, CEO of Immix Biopharma, Inc. (IMMX), bought 4,300 shares at $2.25 each, totaling $9,288.00. This increased his stake to 912,000 shares. Rachman's history includes significant stock options and share purchases. The company's stock has varied, with a fifty-two-week price change of 81.82% and a market cap of $58,059,244. Another insider, Morris Gabriel S, also invested, buying 4,500 shares at $2.23. These transactions may reflect insider confidence in the company's future.
On May 10, 2024, Topline Capital Management, Llc purchased 30,000 shares of Issuer Direct Corporation (ISDR) at $9.97 per share, totaling $300,000. This reflects ongoing investment, as they previously acquired shares at varying prices, indicating confidence in ISDR's potential. Despite a market downturn, with a -16.32% change recently, Topline's actions suggest an optimistic view of the company's future. Issuer Direct Corporation, a technology firm, has a market cap of USD 66,583,940 and remains financially robust with significant gross profits.
Williamson Robert F III, an insider at Perspective Therapeutics, Inc. (CATX), recently acquired 18,601.2941 shares at $0.71 per share, totaling $13,950.97. This non-derivative transaction suggests a direct and confident investment in the company's future. With a history of consistent share purchases over the past year, Williamson's actions reflect a bullish perspective on the Healthcare sector player. The company's stock has seen a 66.67% rise in the last ten days and a 200.0% surge over fifty days. With a robust market cap of USD 83,189,304 and low debt levels, Perspective Therapeutics stands on solid financial ground, making it a potentially attractive option for investors.